Search Within

Yosef Y Tobi

Formats
  1. Journal Article (5)
  2. Meeting Abstract (1)
Groups
  1. Department of Medicine (4)
  2. Solid Tumor Oncology Division (4)
  3. Thoracic Oncology (4)
  4. Department of Pathology and Laboratory Medicine (3)
  5. Nursing (3)
  6. Weinberg Fellows (3)

More Groups

People
  1. Helena Yu (4)
  2. Alex Makhnin (3)
  3. Gregory Riely (3)
  4. Linda Ahn (3)
  5. Mark Kris (3)
  6. Adam Schoenfeld (2)

More People

Years
  1. 2023 (2)
  2. 2022 (1)
  3. 2021 (2)
  4. 2020 (1)
Publications
  1. Annals of Neurology (1)
  2. International Journal of Molecular Sciences (1)
  3. JAMA Oncology (1)
  4. JCO Precision Oncology (1)
  5. JTO Clinical and Research Reports (1)
  6. Nature Communications (1)
Publishers
  1. American Medical Association (1)
  2. American Society of Clinical Oncology (1)
  3. Elsevier BV (1)
  4. MDPI (1)
  5. Nature Publishing Group (1)
  6. Wiley Blackwell (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dementia and the gut: Is there a gut immune imbalance? Can we intervene?
    Meeting Abstract

    Demian, E.; Tobi, Y.; Chalia, P.; Antaki, F.; Talwar, H.; Lawson, M.; McVicker, B.; Tobi, M.
    Annals of Neurology (2023)

    Fulltext@MSK | Save
  • In the SARS-CoV-2 pandora pandemic: Can the stance of premorbid intestinal innate immune system as measured by fecal Adnab-9 binding of p87:Blood ferritin, yielding the FERAD ratio, predict COVID-19 susceptibility and survival in a prospective population database?
    Journal Article

    Tobi, M.; Bluth, M. H.; Rossi, N. F.; Demian, E.; Talwar, H.; Tobi, Y. Y.; Sochacki, P.; Levi, E.; Lawson, M.; McVicker, B.
    International Journal of Molecular Sciences (2023)

    Fulltext@MSK | Save
  • Phase 1 clinical trial of trametinib and ponatinib in patients with NSCLC harboring KRAS mutations
    Journal Article

    Arbour, K. C.; Manchado, E.; Bott, M. J.; Ahn, L.; Tobi, Y.; Ni, A. A.; Yu, H. A.; Shannon, A.; Ladanyi, M.; Perron, V.; more...
    JTO Clinical and Research Reports (2022)

    Fulltext@MSK | Save
  • Erlotinib and trametinib in patients with EGFR-mutant lung adenocarcinoma and acquired resistance to a prior tyrosine kinase inhibitor
    Journal Article

    Luo, J.; Makhnin, A.; Tobi, Y.; Ahn, L.; Hayes, S. A.; Iqbal, A.; Ng, K.; Arcila, M. E.; Riely, G. J.; Kris, M. G.; more...
    JCO Precision Oncology (2021)

    Fulltext@MSK | Save
  • Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
    Journal Article

    Poels, K. E.; Schoenfeld, A. J.; Makhnin, A.; Tobi, Y.; Wang, Y.; Frisco-Cabanos, H.; Chakrabarti, S.; Shi, M.; Napoli, C.; McDonald, T. O.; more...
    Nature Communications (2021)

    Fulltext@MSK | Save
  • Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: A phase 1/2 single-group open-label trial
    Journal Article

    Yu, H. A.; Schoenfeld, A. J.; Makhnin, A.; Kim, R.; Rizvi, H.; Tsui, D.; Falcon, C.; Houck-Loomis, B.; Meng, F.; Yang, J. L.; more...
    JAMA Oncology (2020)

    Fulltext@MSK | Save